Sarcopenia in the Cirrhotic Patient : Current Knowledge and Future Directions
© 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved..
Cirrhosis predisposes to abnormalities in energy, hormonal, and immunological homeostasis. Disturbances in these metabolic processes create susceptibility to sarcopenia or pathological muscle wasting. Sarcopenia is prevalent in cirrhosis and its presence portends significant adverse outcomes including the length of hospital stay, infectious complications, and mortality. This highlights the importance of identification of at-risk individuals with early nutritional, therapeutic and physical therapy intervention. This manuscript summarizes literature relevant to sarcopenia in cirrhosis, describes current knowledge, and elucidates possible future directions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of clinical and experimental hepatology - 13(2023), 1 vom: 01. Jan., Seite 162-177 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Warner Ii, Edgewood R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 02.01.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jceh.2022.06.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351582924 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351582924 | ||
| 003 | DE-627 | ||
| 005 | 20240108140654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jceh.2022.06.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM351582924 | ||
| 035 | |a (NLM)36647414 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Warner Ii, Edgewood R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sarcopenia in the Cirrhotic Patient |b Current Knowledge and Future Directions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Cirrhosis predisposes to abnormalities in energy, hormonal, and immunological homeostasis. Disturbances in these metabolic processes create susceptibility to sarcopenia or pathological muscle wasting. Sarcopenia is prevalent in cirrhosis and its presence portends significant adverse outcomes including the length of hospital stay, infectious complications, and mortality. This highlights the importance of identification of at-risk individuals with early nutritional, therapeutic and physical therapy intervention. This manuscript summarizes literature relevant to sarcopenia in cirrhosis, describes current knowledge, and elucidates possible future directions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE, angiotensin-converting enzyme | |
| 650 | 4 | |a ACE-I, angiotensin-converting enzyme inhibitor | |
| 650 | 4 | |a AKI, acute kidney injury | |
| 650 | 4 | |a ALM, appendicular lean mass | |
| 650 | 4 | |a ARB, angiotensin receptor blocker | |
| 650 | 4 | |a ASM, appendicular skeletal mass | |
| 650 | 4 | |a AT1R, angiotensin type 1 receptor | |
| 650 | 4 | |a AT2R, angiotensin type 2 receptor | |
| 650 | 4 | |a ATP, adenosine-5′-triphosphate | |
| 650 | 4 | |a AWGS, Asian Working Group for Sarcopenia | |
| 650 | 4 | |a BCAA, branched chained amino acids | |
| 650 | 4 | |a BIA, bioelectrical impedance analysis | |
| 650 | 4 | |a BMI, body mass index | |
| 650 | 4 | |a CART, classification and regression tree | |
| 650 | 4 | |a CKD, chronic kidney disease | |
| 650 | 4 | |a CRP, C-reactive protein | |
| 650 | 4 | |a DEXA, dual energy X-ray absorptiometry | |
| 650 | 4 | |a EAA, essential amino acids | |
| 650 | 4 | |a ESPEN-SIG, European Society for Clinical Nutrition and Metabolism Special Interests Groups | |
| 650 | 4 | |a ESRD, end-stage renal disease | |
| 650 | 4 | |a EWGSOP, European Working Group on Sarcopenia in Older People | |
| 650 | 4 | |a FAD, flavin adenine dinucleotide | |
| 650 | 4 | |a FADH2, flavin adenine dinucleotide +2 hydrogen | |
| 650 | 4 | |a FNIH, Foundation for the National Institutes of Health | |
| 650 | 4 | |a GTP, guanosine-5′-triphosphate | |
| 650 | 4 | |a GnRH, gonadotrophin-releasing hormone | |
| 650 | 4 | |a HCC, hepatocellular carcinoma | |
| 650 | 4 | |a HPT, hypothalamic-pituitary-testicular | |
| 650 | 4 | |a IFN-γ, interferon γ | |
| 650 | 4 | |a IGF-1, insulin-like growth factor 1 | |
| 650 | 4 | |a IL-1, interleukin-1 | |
| 650 | 4 | |a IL-6, interleukin-6 | |
| 650 | 4 | |a IWGS, International Working Group on Sarcopenia | |
| 650 | 4 | |a LH, luteinizing hormone | |
| 650 | 4 | |a MELD, Model for End-Stage Liver Disease | |
| 650 | 4 | |a MuRF1, muscle RING-finger-1 | |
| 650 | 4 | |a NAD, nicotinamide adenine dinucleotide | |
| 650 | 4 | |a NADH, nicotinamide adenine dinucleotide + hydrogen | |
| 650 | 4 | |a NADPH, nicotinamide adenine dinucleotide phosphate | |
| 650 | 4 | |a NAFLD, non-alcoholic fatty liver disease | |
| 650 | 4 | |a NASH, non-alcoholic steatohepatitis | |
| 650 | 4 | |a NF-κβ, nuclear factor κβ | |
| 650 | 4 | |a NHANES, National Health and Nutritional Examination Survey | |
| 650 | 4 | |a PMI, psoas muscle index | |
| 650 | 4 | |a PMTH, psoas muscle thickness | |
| 650 | 4 | |a RAAS, renin-angiotensin-aldosterone system | |
| 650 | 4 | |a ROS, reactive oxygen species | |
| 650 | 4 | |a SARC-F, Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls | |
| 650 | 4 | |a SHBG, sex hormone binding globulin | |
| 650 | 4 | |a SMI, skeletal muscle index | |
| 650 | 4 | |a SNS, sympathetic nervous system | |
| 650 | 4 | |a SPPB, Short Performance Physical Battery | |
| 650 | 4 | |a TNF-α, tumor necrosis factor α | |
| 650 | 4 | |a UCSF, University of California, San Francisco | |
| 650 | 4 | |a UNOS, United Network of Organ Sharing | |
| 650 | 4 | |a cirrhosis | |
| 650 | 4 | |a energy | |
| 650 | 4 | |a mTOR, mammalian target of rapamycin | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a muscle | |
| 650 | 4 | |a sarcopenia | |
| 700 | 1 | |a Satapathy, Sanjaya K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical and experimental hepatology |d 2011 |g 13(2023), 1 vom: 01. Jan., Seite 162-177 |w (DE-627)NLM214404560 |x 0973-6883 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:162-177 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jceh.2022.06.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 01 |c 01 |h 162-177 | ||